Back to today’s briefing

Story perspectives

EU Approves Groundbreaking Cancer Treatments, Boosting Survival Rates

2/6/2025

44 8

Summary

Story summary

In a significant breakthrough, the European Commission has greenlit serplulimab for extensive-stage small cell lung cancer, demonstrating enhanced survival rates in a phase 3 trial. Simultaneously, Eli Lilly in Korea is pushing for expedited approval of imlunestrant for breast cancer, promising greater access to cutting-edge treatments. These milestones mark a hopeful stride in the fight against cancer.

1 of 1

Story summary

In a significant breakthrough, the European Commission has greenlit serplulimab for extensive-stage small cell lung cancer, demonstrating enhanced survival rates in a phase 3 trial. Simultaneously, Eli Lilly in Korea is pushing for expedited approval of imlunestrant for breast cancer, promising greater access to cutting-edge treatments. These milestones mark a hopeful stride in the fight against cancer.